Similar articles for PMID: 31332344

Year	Number of Results
2011	2
2013	1
2014	5
2015	12
2016	16
2017	18
2018	9
2019	12
2020	5
2021	3
2024	0

1

PARP inhibition - opportunities in pancreatic cancer.

Pant S, Maitra A, Yap TA. Pant S, et al. Nat Rev Clin Oncol. 2019 Oct;16(10):595-596. doi: 10.1038/s41571-019-0257-6. Nat Rev Clin Oncol. 2019. PMID: 31332344 No abstract available.

2

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F. Schreiber V, et al. Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Bull Cancer. 2015. PMID: 26384693 Review. French.

3

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. Ann Oncol. 2017. PMID: 27687312 Free article. No abstract available.

4

PARP Inhibitors in Ovarian Cancer.

Dekker TJA. Dekker TJA. N Engl J Med. 2020 Apr 16;382(16):1573-1574. doi: 10.1056/NEJMc2000644. N Engl J Med. 2020. PMID: 32294363 No abstract available.

5

PARP Inhibitors in Ovarian Cancer.

Haines IE, Gabor Miklos GL. Haines IE, et al. N Engl J Med. 2020 Apr 16;382(16):1573. doi: 10.1056/NEJMc2000644. N Engl J Med. 2020. PMID: 32294362 No abstract available.

6

Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.

Parkes EE, Kennedy RD. Parkes EE, et al. Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28. Oncologist. 2016. PMID: 27022037 Free PMC article. Review.

7

EMBRACing a new PARP inhibitor?

Romero D. Romero D. Nat Rev Clin Oncol. 2018 Nov;15(11):655. doi: 10.1038/s41571-018-0090-3. Nat Rev Clin Oncol. 2018. PMID: 30177682 No abstract available.

8

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.

Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW. Lohse I, et al. PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016. PLoS One. 2016. PMID: 28033382 Free PMC article.

9

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH. Yuan B, et al. Cancer Lett. 2017 Feb 1;386:47-56. doi: 10.1016/j.canlet.2016.11.010. Epub 2016 Nov 12. Cancer Lett. 2017. PMID: 27847302

10

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ. Min A, et al. Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y. Breast Cancer Res. 2015. PMID: 25888415 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

73 results

Results by year